Literature DB >> 21086573

Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.

Yubao Wang1, Kermit V Speeg, William Kenneth Washburn, Glenn Halff.   

Abstract

A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21086573      PMCID： PMC2988248          DOI： 10.3748/wjg.v16.i43.5518

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  18 in total

1.  Sirolimus therapy in liver transplant patients: an initial experience at a single center.

Authors:  A Nocera; E Andorno; A Tagliamacco; N Morelli; G Bottino; F Ravazzoni; M Casaccia; S Barocci; S Alice; G Santori; R Ghirelli; U Valente
Journal:  Transplant Proc       Date:  2008 Jul-Aug       Impact factor: 1.066

Review 2.  Targeted agents for the treatment of advanced renal cell carcinoma.

Authors:  M Staehler; K Rohrmann; N Haseke; C G Stief; M Siebels
Journal:  Curr Drug Targets       Date:  2005-11       Impact factor: 3.465

3.  Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation.

Authors:  Wolfgang Sieghart; Thorsten Fuereder; Katharina Schmid; Daniel Cejka; Johannes Werzowa; Fritz Wrba; Xiaowei Wang; Diego Gruber; Susanne Rasoul-Rockenschaub; Markus Peck-Radosavljevic; Volker Wacheck
Journal:  Transplantation       Date:  2007-02-27       Impact factor: 4.939

4.  Liver transplantation for hepatocellular carcinoma: the Kyoto experience.

Authors:  Yasutsugu Takada; Shinji Uemoto
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-08-26       Impact factor: 7.027

5.  Epidemiology of hepatocellular carcinoma in Hispanics in the United States.

Authors:  Hashem B El-Serag; Melvin Lau; Karl Eschbach; Jessica Davila; James Goodwin
Journal:  Arch Intern Med       Date:  2007-10-08

6.  Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9.

Authors:  Jing-Song Chen; Qian Wang; Xin-Hui Fu; Xiao-Hui Huang; Xi-Lin Chen; Liang-Qi Cao; Lian-Zhou Chen; Hao-Xiang Tan; Wen Li; Jiong Bi; Long-Juan Zhang
Journal:  Hepatol Res       Date:  2009-02       Impact factor: 4.288

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Systemic therapy for hepatocellular carcinoma.

Authors:  Melanie B Thomas
Journal:  Cancer J       Date:  2008 Mar-Apr       Impact factor: 3.360

9.  The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.

Authors:  Ledu Zhou; Yun Huang; Jingdong Li; Zhiming Wang
Journal:  Med Oncol       Date:  2009-03-20       Impact factor: 3.064

10.  RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma.

Authors:  Hung Huynh; K H Pierce Chow; Khee Chee Soo; Han Chong Toh; Su Pin Choo; Kian Fong Foo; Donald Poon; Van Chanh Ngo; Evelyn Tran
Journal:  J Cell Mol Med       Date:  2008-05-07       Impact factor: 5.310
View more
  6 in total

Review 1.  Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.

Authors:  Nicola de'Angelis; Filippo Landi; Maria Clotilde Carra; Daniel Azoulay
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 2.  Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.

Authors:  Yasunobu Matsuda; Takafumi Ichida; Manabu Fukumoto
Journal:  Med Mol Morphol       Date:  2011-09-16       Impact factor: 2.309

Review 3.  Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.

Authors:  Richard S Finn
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

Review 4.  Role of organ transplantation in the treatment of malignancies: hepatocellular carcinoma as the most common tumour treated with transplantation.

Authors:  Gyula Végso; Dénes Görög; Imre Fehérvári; Balázs Nemes; Attila Doros; Róbert Miklós Langer; László Kóbori
Journal:  Pathol Oncol Res       Date:  2011-09-07       Impact factor: 3.201

Review 5.  Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.

Authors:  Jian-Jun Gao; Zhen-Yan Shi; Ju-Feng Xia; Yoshinori Inagaki; Wei Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

6.  Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.

Authors:  Quan-Lin Li; Fang-Ming Gu; Zheng Wang; Jia-Hao Jiang; Li-Qing Yao; Chang-Jun Tan; Xiao-Yong Huang; Ai-Wu Ke; Zhi Dai; Jia Fan; Jian Zhou
Journal:  PLoS One       Date:  2012-03-09       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.